下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

用于乳腺癌治疗的可注射水凝胶：从肿瘤微环境响应性与主动靶向药物递送到免疫治疗与诊疗一体化

Injectable Hydrogels for Breast Cancer Therapy: From Tumor Microenvironment-Responsive and Actively Targeted Drug Delivery to Immunotherapy and Theran

CAR-T 细胞治疗乳腺癌的进展与挑战：从分子设计到临床应用

Advances and challenges in CAR-T cell therapy for breast cancer: from molecular design to clinical application.

嵌合抗原受体自然杀伤（CAR-NK）细胞治疗乳腺癌的疗效与安全性评价：系统综述与荟萃分析

Evaluation of Efficacy and Safety of Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cells in Breast Cancer: A Systematic Review and Meta-Analysis.

乳腺癌管理中的 CAR-T 细胞治疗：拓展视野并克服血液系统肿瘤之外的挑战

CAR-T cell therapy in breast cancer management: expanding horizon and overcoming challenges beyond hematologic cancers.

肿瘤相关 Tn 和 STn 抗原：从分子机制到精准诊断与治疗

Tumor-associated Tn and STn antigens: from molecular mechanism to precision diagnosis and treatment.

Tn/STn 抗原在肿瘤发生和免疫逃逸中发挥关键作用，在诊断和治疗方面具有巨大潜力。未来研究应集中于阐明其潜在机制、开发创新检测技术，并促进多学科合作，以推动基于 Tn/STn 抗原的肿瘤分子分型、精准靶向治疗和疗效预测系统的发展，从而为癌症诊断和治疗提供新方向。

大麻二酚经 EGFR 抑制与 FAS 上调增强三阴性乳腺癌细胞对 NK 细胞介导杀伤的敏感性

Cannabidiol sensitizes triple-negative breast cancer cells to NK cell-mediated killing via EGFR inhibition and FAS upregulation.

这些发现表明，CBD 通过破坏 EGFR 信号传导并促进凋亡，有望成为 TNBC 的潜在抗癌药物。然而，仍需进一步研究以优化其治疗窗并尽量减少不良反应，特别是关于其对免疫细胞的潜在细胞毒性。

癌症治疗中的三剑客：药代动力学、药效学和个体化方法

The Three Musketeers in Cancer Therapy: Pharmacokinetics, Pharmacodynamics and Personalised Approach.

三阴性乳腺癌不良预后相关的分子靶点与治疗（综述）

Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review).

嵌合抗原受体 NK 细胞用于乳腺癌免疫治疗

Chimeric antigen receptor NK cells for breast cancer immunotherapy.